- Home
- SUGP vs GOVX Comparison
SUGP vs GOVX Comparison
Compare SUGP & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- GOVX
- Stock Information
- Founded
- SUGP 1998
- GOVX 2001
- Country
- SUGP Hong Kong
- GOVX United States
- Employees
- SUGP N/A
- GOVX N/A
- Industry
- SUGP
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- GOVX Health Care
- Exchange
- SUGP NYSE
- GOVX Nasdaq
- Market Cap
- SUGP 20.3M
- GOVX 23.8M
- IPO Year
- SUGP 2024
- GOVX N/A
- Fundamental
- Price
- SUGP $1.17
- GOVX $2.22
- Analyst Decision
- SUGP
- GOVX Strong Buy
- Analyst Count
- SUGP 0
- GOVX 5
- Target Price
- SUGP N/A
- GOVX $14.20
- AVG Volume (30 Days)
- SUGP 510.4K
- GOVX 759.4K
- Earning Date
- SUGP 01-28-2025
- GOVX 02-27-2025
- Dividend Yield
- SUGP N/A
- GOVX N/A
- EPS Growth
- SUGP N/A
- GOVX N/A
- EPS
- SUGP 0.10
- GOVX N/A
- Revenue
- SUGP $20,252,232.00
- GOVX $3,090,161.00
- Revenue This Year
- SUGP N/A
- GOVX N/A
- Revenue Next Year
- SUGP N/A
- GOVX $150.51
- P/E Ratio
- SUGP $11.40
- GOVX N/A
- Revenue Growth
- SUGP N/A
- GOVX N/A
- 52 Week Low
- SUGP $0.76
- GOVX $1.09
- 52 Week High
- SUGP $5.86
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- SUGP 46.38
- GOVX 44.57
- Support Level
- SUGP $1.09
- GOVX $2.04
- Resistance Level
- SUGP $1.26
- GOVX $2.32
- Average True Range (ATR)
- SUGP 0.14
- GOVX 0.18
- MACD
- SUGP 0.01
- GOVX -0.02
- Stochastic Oscillator
- SUGP 34.15
- GOVX 25.35
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.